Objective:

To explore the evolving analytical needs in peptide therapeutics, particularly GLP-1 receptor agonists, and the urgent role of high-resolution mass spectrometry (HRAM) in addressing these challenges.

Key Findings:

• HRAM improves selectivity in complex matrices and allows for reliable low-picomolar LLOQs, enhancing overall analytical performance.
• The integration of HRAM with triple-quads enhances method development speed and confidence in quantitative analysis, particularly for challenging samples.
• Emerging best practices include optimized sample prep techniques, such as specific extraction methods, and automated workflows for small-volume analysis.

Interpretation:

The shift towards HRAM in peptide bioanalysis reflects the growing complexity and demands of peptide therapeutics, necessitating flexible and efficient analytical methods to meet these challenges.

Limitations:

• No single mass spectrometry tool can address all analytical challenges; both HRAM and triple-quads have specific strengths and weaknesses that must be understood.
• Complex matrices and novel peptide formulations present ongoing challenges for accurate analysis, highlighting the need for continued innovation in analytical techniques.

Conclusion:

The collaboration between Veloxity Labs and SCIEX aims to enhance the analytical capabilities for peptide therapeutics, ensuring compliance with regulatory standards while improving speed and selectivity, underscoring the importance of collaborative efforts in this evolving field.